NCT00999336View on ClinicalTrials.gov

A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Renal Impairment
Interventions
DRUG

Betrixaban

80 mg betrixaban qd for 8 days

Trial Locations (1)

Unknown

APEX GmbH, Munich

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Portola Pharmaceuticals

INDUSTRY

NCT00999336 - A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment | Biotech Hunter | Biotech Hunter